Patients receiving subcutaneous daratumumab have less chair time and premedication than those receiving IV formulation, says ...

We searched for studies that compared the benefits and harms of daratumumab plus antimyeloma medicines with the same antimyeloma medicines alone in adults with a newly confirmed diagnosis of multiple ...

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease ...

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, according to Gina Fries, PA-C. The reduction of chair time that subcutaneous ...

While Amgen’s monthly obesity candidate MariTide helped patients lose significant amounts of weight in a phase 2 study, prevalent gastrointestinal side effects are leading the company to use a ...